Home
Journal Club
Explore
More
Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Language
English
English
LF
Lesley Farrington
PARP inhibition in cancer therapy
Johnson & Johnson (United States)
Share
Follow
Claim This Profile
About
Research focus
PARP inhibition in cancer therapy
Impact
5 pubs · 185 cites · h-index 2
Affiliations
Johnson & Johnson (United States)
Janssen (United States)
Theravance Biopharma (United States)
Publications
Recent publications by Lesley Farrington
Clinical validity of FoundationOne CDx assay to identify HRR -positive or BRCA -positive mCSPC patients in the phase 3 AMPLITUDE study.
Journal of Clinical Oncology · Sun,
In Vitro Activity of TD-6424 againstStaphylococcus aureus
Antimicrobial Agents and Chemotherapy · Fri,
Multivalent Drug Design. Synthesis and In Vitro Analysis of an Array of Vancomycin Dimers
Journal of the American Chemical Society · Thu,